



















1 <sup>st</sup> call for help Priority Follow-Up Lines out List of lines OT/PT Financial Toxicity	they need to I I, H2 blocker, e 4. Unintentional Discontinuat	tion by Medication Gro No. (%) o Without ICU Stay	", or op	
Priority Follow-Up       Lines out       List of lines       OT/PT       Financial Toxicity       Exercise	<b>e 4.</b> Unintentional Discontinuat	tion by Medication Gro No. (%) o Without ICU Stay	up and ICU Stay f Patients With	
Lines out List of lines OT/PT Financial Toxicity	cation discontinued <sup>b</sup>	No. (%) o Without ICU Stay	f Patients With	AOR (95% CI) <sup>a</sup>
CT/PT Financial Toxicity Exercise	cation discontinued <sup>b</sup>	No. (%) o Without ICU Stay	f Patients With	AOR (95% CI) <sup>a</sup>
OT/PT Financial Toxicity Exercise		Without ICU Stay	With	AOR (95% CI) <sup>a</sup>
OT/PT Financial Toxicity				
Exercise	la un is	11 793 (13.5)	1484 (14.6)	1.11 (1.05-1.18)
Exercise	ntiplatelets or anticoagulants	5012 (19.1)	552 (22.8)	1.25 (1.13-1.39)
Exercise	evothyroxine	6217 (12.1)	614 (15.0)	1.29 (1.17-1.41)
Exercise	espiratory inhalers	211 (4.4)	20 (5.4)	1.23 (0.76-1.97)
Exercise	astric acid suppressors	6724 (12.7)	670 (15.4)	1.26 (1.15-1.37)
Big 5 Readmit	viations: AOR, adjusted odds ratio; CI, sted for age, sex, low-income status (c 24 175), number of different prescriptior e is detailed information for each medic	defined as individual income ns, and number of primary of	<\$16018 or combinate are physician or spec	cialist visits.
Dig o Rodullin				
Info Sheet				
	Bell (2011) JAMA 306(8)	1.840-847: Scalos (201	5)   Con Intern	Med 21/2).106_202
	Deli (2011) JAIVIA 500(6)			
11		PLoS ONF https://doi		

Restart / Titrate Stop <b>Anticoag</b>	What's the plan for anticoagulation? Was it empiric, or was a clot found?
1 <sup>st</sup> call for help Priority Follow-Up Lines out List of lines	Critical care, ICU, or equivalent Maticoagulation is appropriate, but the level of anticoagulation (prophylactic dose, intermediate dose, or full-dose) is controversial due to high risk of DVT/PE and lack of high-quality data on efficacy and safety
OT/PT Financial Toxicity	<ul> <li>Refer to institutional guidelines</li> <li>Enroll in a clinical trial if possible</li> <li>Refer to UpToDate for further discussion</li> </ul>
Exercise Big 5 Readmit Info Sheet	
	Cuker & Peyvandi (2020) UpToDate last updated 11 May 2020 https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-hypercoagulability

Restart / Titrate	What is the plan for who the patient should call prior to their first primary care			
Stop	provider visit?			
Anticoag				
	What are the absolutely key follow-up			
1 <sup>st</sup> call for help	they need?			
<b>Priority Follow-Up</b>	· · · <b>·</b>	-		
Lines out List of lines OT/PT		WHO ARE YOU GOING TO CALL?		
Financial Toxicity		GOING TO CALL?		
	Please pick the 1-3 things they really must			
Exercise	do, and make sure they are set-up			
Big 5 Readmit	BEFORE they leave the hospital.			
Info Sheet		ncy icave the hospit	а.	

Restart / Titrate Stop	Are the lines and "temporary de out?	vices" all		
Anticoag		Unaware of CVC Presence*		
	By provider			
1 <sup>st</sup> call for help	House staff	39/238 (16.4)		
· · · · · · · · · · · · · · · · · · ·	Interns	22/115 (19.1)		
Priority Follow-Up	Residents	17/123 (13.8)		
	General medicine teaching attending	33/128 (25.8)		
	Hospitalist	18/59 (30.5)		
Lines out	By service			
List of lines	General medicine teaching attending or hospitalist	49/187 (26.2)		
List of lines	Critical care	16/127 (12.6)		
	Other subspecialties	25/111 (22.5)		
	ICU	16/127 (12.6)		
OT/PT	Non-ICU setting	74/298 (24.8)		
Financial Toxicity	PICC	60/239 (25.1)		
I manolal toxicity	Triple-lumen catheter	30/192 (15.6)		
Exercise Big 5 Readmit Info Sheet	Do they have a written list of all lines/tubes/drains that they had this hospitalization?			
	Chopra (2014) A	nn Int Med 161(8):562-7		











